MI
XENE icon

Motiv8 Investments’s Xenon Pharmaceuticals XENE Stock Holding History

Motiv8 Investments’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2 Buy
+40
New +$1.68K ﹤0.01% 789

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Motiv8 Investments's XENE Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Xenon Pharmaceuticals (XENE) in Q4 2025: 40 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #789 among its holdings.

246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Motiv8 Investments held 40 shares of Xenon Pharmaceuticals worth $2 as of Q4 2025.
  • Xenon Pharmaceuticals was a new Motiv8 Investments position in Q4 2025.
  • Xenon Pharmaceuticals made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #789 holding.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.